Ireland
--:--IST
Recruiting Phase 1

SAR447971 First-in-human Study

NCT07629336 · tracked via the Priya Life Science Netherlands tracker
Sponsor
Phase
Phase 1
Started
2026-05-26
Last updated
2026-10-27

Condition(s) studied

HidradenitisHealthy Volunteers

Investigational drug(s) / intervention(s)

SAR447971Placebo

SAR447971: Pharmaceutical form: Tablet Route of administration: Oral

Placebo: Pharmaceutical form: Tablet Route of administration: Oral

Study summary

SAD20411 is a single-center, first-in-human, double-blind, randomized, placebo-controlled, sequential single ascending dose study in healthy male and/or female participants with a pilot food effect investigation.

MAD20412 is a single-center, double-blind, randomized, placebo-controlled, sequential multiple ascending dose study in healthy male and/or female participants.

MAD24339 is an open-label, sequential multiple ascending dose study in hidradenitis suppurativa (HS) male and/or female participants.

Number of participants The total expected number of healthy participants is approximately 102 and the total number of HS participants is expected to be approximately 20.

* SAD20411 will enroll up to 54 participants
* MAD20412 will enroll up to 48 participants
* MAD24339 will enroll up to 20 participants

Duration of study The anticipated study duration per participant is up to approximately 10 weeks in SAD20411 and MAD20412, and up to approximately 12 weeks in MAD24339.

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
Accepted
Inclusion Criteria: For participation in SAD20411/MAD20412: * Male and/or female participant, between 18 and 55 years of age, inclusive at the time of signing the ICF. * Appearing healthy by a comprehensive clinical assessment (detailed medical history and complete physical examination). For participation in MAD24339: * Age ≥18 and ≤65 years of age at the time of signing informed consent. * A diagnosis of HS made by a dermatologist at least 6 months prior to baseline visit. * HS lesions present in at least 2 distinct anatomic areas (e. g., left and right axilla; or left axilla and left inguino-crural fold), one of which must be Hurley Stage II or Hurley Stage III. * Total AN count of ≥4 at the baseline visit. - Draining tunnel count of ≤20 at the baseline visit. Exclusion Criteria: For participation in SAD20411/MAD20412: Any history or presence of clinically relevant cardiovascular, pulmonary, gastrointestinal, dermatologic, hepatic, renal, metabolic, hematological, neurological, osteomuscular, articular, psychiatric, systemic, ocular, gynecologic (if female) or signs of acute illness. Active or chronic infection requiring systemic treatment within 4 weeks prior to baseline. Known history of immunosuppression or suspected current immunosuppression. For participation in MAD24339: * Any active skin disease or condition other than HS (including but not limited to inflammatory skin diseases and cutaneous infections) that may interfere with assessment of HS. * Any active or chronic infection requiring systemic treatment (eg, antibiotics, antivirals, antifungals, antihelminthics) within 30 days prior to baseline. * Use of prescription topical therapies for the treatment of HS within 14 days prior to the baseline visit. * Treatment with systemic antibiotics for HS within 14 days prior to the baseline visit. * Non-biologic systemic therapies with potential therapeutic impact on HS \<28 days or five half-lives prior to baseline visit. * Any history of prior treatment with any systemic biologic with a potential therapeutic impact on HS. The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Primary outcome measure(s)

  • SAD20411: Incidence of treatment emergent adverse events (TEAEs) — Day 1 to Day 15
  • SAD20411: Incidence of clinically significant abnormalities in clinical laboratory evaluations (hematology, biochemistry, coagulation, urinalysis) — Day 1 to Day 15
  • SAD20411: Incidence of clinically significant abnormalities in vital signs — Day 1 to Day 15
  • SAD20411: Incidence of clinically significant abnormalities in ECG (heart rate, PR, QRS, QT, QTcF) — Day 1 to Day 15
  • MAD20412: Incidence of treatment emergent adverse events (TEAEs) — Day 1 to Day 29
  • MAD20412: Incidence of clinically significant abnormalities in clinical laboratory evaluations (hematology, biochemistry, coagulation, urinalysis) — Day 1 to Day 29
  • MAD20412: Incidence of clinically significant abnormalities in vital signs — Day 1 to Day 29
  • MAD20412: Incidence of clinically significant abnormalities in ECG (heart rate, PR, QRS, QT, QTcF) — Day 1 to Day 29
  • MAD24339: Incidence of treatment emergent adverse events (TEAEs) — Day 1 to Day 42
  • MAD24339: Incidence of clinically significant abnormalities in clinical laboratory evaluations (hematology, biochemistry, coagulation, urinalysis) — Day 1 to Day 42
  • MAD24339: Incidence of clinically significant abnormalities in vital signs — Day 1 to Day 42
  • MAD24339: Incidence of clinically significant abnormalities in ECG (heart rate, PR, QRS, QT, QTcF) — Day 1 to Day 42

Trial sites (1)

FacilityCityRegionStatus
Investigational Site Number: 5280001 Leiden Netherlands Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07629336 on ClinicalTrials.gov ↗ ← All trials in the Netherlands